Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Jefferson Research
$20.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Akorn Inc divests ECR Pharmaceuticals to Valeant


Friday, 20 Jun 2014 11:11am EDT 

Akorn Inc:Says it sold its subsidiary, ECR Pharmaceuticals (ECR), to Valeant Pharmaceuticals for $41 mln in cash and assumption of certain liabilities.ECR, which promotes certain branded pharmaceuticals through its sales force, was acquired through the acquisition of Hi-Tech Pharmacal. 

Company Quote

44.38
1.61 +3.76%
24 Oct 2014